제 2형 당뇨 환자에서 Sitagliptin과 Sulfonylurea계 약물 병용 시혈당 조절 효과와 저혈당 발현에 관한 연구
Effectiveness and Incidence of Hypoglycemia in the Combination of Sitagliptin and Sulfonylurea, in Patients with Type 2 Diabetes Mellitus
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Sitagliptin, which inhibits dipeptidyl polypeptidase-4 and stimulate thesecretion of insulin, is primarily used as a combination therapy with other oral hypoglycemicdrugs. Sitagliptin is known to have lower incidence in hypoglycemia compared to other oralhypoglycemic drugs. However, several studies suggest that combination therapy includingsitagliptin, can cause hypoglycemia. The aim of this study is to analyze the effectiveness and thefrequency of hypoglycemia in Korean patients with type 2 diabetes treated with sitagliptin andsulfonylurea. Methods : From August 2008 to April 2010, we retrospectively reviewed the electronic medical records of type 2 diabetes patients who were prescribed sulfonylurea and sitagliptin over a periodof 6 months at Seoul National University Hospital. We excluded patients who had been usinginsulin as well as those, who had ESRD or kidney transplantation. Results : A total of 232 Korean patients were enrolled in this study. The effectiveness in thereduction of blood glucose was statistically significant (P<0.05). In the sulfonylurea maintenancegroup (n=206), 10 patients experienced hypoglycemia, however two of them were not related tothe medicine. In the sulfonylurea reduction group (n=26), one patient who had problems of alcoholabuse, experienced hypoglycemia. Therefore, he recovered from hypoglycemia after quittingdrinking. Conclusions : In this study, the combination therapy of sitagliptin and sulfonylurea significantlyimproved glycemic control. Yet, hypoglycemia occurred in some patients after adding sitagliptin.
Abstract
Background : Sitagliptin, which inhibits dipeptidyl polypeptidase-4 and stimulate thesecretion of insulin, is primarily used as a combination therapy with other oral hypoglycemicdrugs. Sitagliptin is known to have lower incidence in hypoglycemia compared to other oralhypoglycemic drugs. However, several studies suggest that combination therapy includingsitagliptin, can cause hypoglycemia. The aim of this study is to analyze the effectiveness and thefrequency of hypoglycemia in Korean patients with type 2 diabetes treated with sitagliptin andsulfonylurea. Methods : From August 2008 to April 2010, we retrospectively reviewed the electronic medical records of type 2 diabetes patients who were prescribed sulfonylurea and sitagliptin over a periodof 6 months at Seoul National University Hospital. We excluded patients who had been usinginsulin as well as those, who had ESRD or kidney transplantation. Results : A total of 232 Korean patients were enrolled in this study. The effectiveness in thereduction of blood glucose was statistically significant (P<0.05). In the sulfonylurea maintenancegroup (n=206), 10 patients experienced hypoglycemia, however two of them were not related tothe medicine. In the sulfonylurea reduction group (n=26), one patient who had problems of alcoholabuse, experienced hypoglycemia. Therefore, he recovered from hypoglycemia after quittingdrinking. Conclusions : In this study, the combination therapy of sitagliptin and sulfonylurea significantlyimproved glycemic control. Yet, hypoglycemia occurred in some patients after adding sitagliptin.
참고문헌 (18)
- "National statics of Health insurance of 2010 in South Korea"[URL]
- Drab S.R, "Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects", Pharmacotherapy, 30, pp.609~624 (2010)
- Gary A. Herman, "Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses", Clin Pharmacol, 78(6), pp.675~688 (2005)
- Nauck M.A., "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial", Diabetes Obes Metab, 9, pp.194~205 (2007)
- Hermansen K., "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin", Diabetes Obesity and Metabolism, 9, pp.733~745 (2007)
- Whitley H.P, "Hypoglycemia associated with off-label sitagliptin use", International Medical Case Reports Journal, 1, pp.3~5 (2008)
- "Januvia Insertion Paper" (2014)[URL]
- Guettier J.M, "Hypoglycemia", Endocrinology and Metabolism Clinics of North America, 35(4), pp.753~766 (2006)
- Raz I., "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus", Diabetologia, 49, pp.2564~2571 (2006)
- "Proper use of incretin and sulfonylurea drug"[URL]
- Sato D., "Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan", Drug Saf, 36(8), pp.605~615 (2013)
- Takahara M, "Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy", Endocr J., 59(12), pp.1131~1136 (2012)
- "JANUVIA 25mg, 50mg, 100mg film-coated tablets"[URL]
- Krepinsky J., "Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with endstage renal disease", Am J Kidney Dis, 35(3), pp.500~505 (2000)
- Raz I., "Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes", Current Medical Research and Opinion, 24(2), pp.537~550 (2008)
- Currie C.J, "Survival as a function of HbA1C in people with type 2 diabetes: a retrospective cohort study", The Lancet, 375, pp.481~489 (2010)
- "Lexicomp online"[URL]